Coeptis Therapeutics (NASDAQ:COEP – Get Free Report) is one of 286 public companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its competitors? We will compare Coeptis Therapeutics to related companies based on the strength of its dividends, valuation, institutional ownership, risk, earnings, profitability and analyst recommendations.
Insider and Institutional Ownership
13.9% of Coeptis Therapeutics shares are held by institutional investors. Comparatively, 50.6% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 21.5% of Coeptis Therapeutics shares are held by company insiders. Comparatively, 16.1% of shares of all “Biological products, except diagnostic” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Analyst Recommendations
This is a summary of current recommendations for Coeptis Therapeutics and its competitors, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Coeptis Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
Coeptis Therapeutics Competitors | 1377 | 4432 | 11674 | 202 | 2.61 |
Valuation and Earnings
This table compares Coeptis Therapeutics and its competitors gross revenue, earnings per share (EPS) and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
Coeptis Therapeutics | $80,000.00 | -$21.27 million | -0.46 |
Coeptis Therapeutics Competitors | $570.06 million | -$31.62 million | 6.83 |
Coeptis Therapeutics’ competitors have higher revenue, but lower earnings than Coeptis Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Risk & Volatility
Coeptis Therapeutics has a beta of -0.89, suggesting that its share price is 189% less volatile than the S&P 500. Comparatively, Coeptis Therapeutics’ competitors have a beta of 1.05, suggesting that their average share price is 5% more volatile than the S&P 500.
Profitability
This table compares Coeptis Therapeutics and its competitors’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Coeptis Therapeutics | N/A | -794.75% | -322.86% |
Coeptis Therapeutics Competitors | -4,563.17% | -203.44% | -44.93% |
Summary
Coeptis Therapeutics competitors beat Coeptis Therapeutics on 7 of the 13 factors compared.
About Coeptis Therapeutics
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. is headquartered in Wexford, Pennsylvania.
Receive News & Ratings for Coeptis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coeptis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.